Key clinical point: Long-term follow-up shows ixekizumab efficacy in moderate to severe psoriasis.
Major finding: At 4 years, 66.5% of patients on ixekizumab for psoriasis achieved Psoriasis Area and Severity Index 100.
Study details: A long-term extension of the UNCOVER-3 double-blind, multicenter, phase 3 study in 1,346 individuals with psoriasis.
Disclosures: The study was funded by Eli Lilly, which manufactures ixekizumab. Two authors were employees of Eli Lilly and own company stocks. The remaining three authors reported receiving research funding and consultancies from different pharmaceutical companies, including Eli Lilly.
Lebwohl MG et al. J Eur Acad Dermatol Venereol. 2019 Sep 3. doi: 10.1111/jdv.15921.
Durability of improvement and the absence of serious side‐effects with continuous use of an agent are important considerations when choosing a therapy for psoriasis. The long term results with ixekizumab corroborate previously reported results in patients with moderate‐to‐severe psoriasis. Very high responses were observed with various efficacy endpoints, such as PASI 75, 90, 100 and sPGA clear or almost clear, regardless of the statistical analyses performed. Similar results were also observed in patients with challenging areas to treat such as nails, scalp, and palmoplantar. Furthermore, the majority of patients also reported no itch. The rates of inflammatory bowel disease were very low in these studies (0.3%). The use of an IL-17 inhibitor such as ixekizumab to treat psoriasis is an excellent option.—Paul S. Yamauchi, MD, PhD; Clinical Assistant Professor of Dermatology David Geffen School of Medicine at UCLA; Harbor-UCLA Medical Center Division of Dermatology; Adjunct Associate Professor John Wayne Cancer Institute.